Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VIi
Guillet, B.; Pinganaud, C.; Proulle, V.; Dreyfus, M.; Lambert, T.
Thrombosis and Haemostasis 88(4): 698-699
2002
ISSN/ISBN: 0340-6245 PMID: 12362252 Document Number: 548727
Document emailed within 1 workday
Related Documents
Arkin, S.; Blei, F.; Fetten, J.; Foulke, R.; Gilchrist, G.S.; Heisel, M.A.; Key, N.; Kisker, C.T.; Kitchen, C.; Shafer, F.E.; Shah, P.C.; Strickland, D. 2000: Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 11(3): 255-259Škunca, Željka.; Peraica, A.Planinc. 2016: Treatment of Severe Acquired Haemophilia A with Immunosuppressive Agent: A Case Report of One Patient Collegium Antropologicum 40(2): 139-143
Ingerslev, J.; Thykjaer, H.; Kudsk Jensen, O.; Fredberg, U. 1998: Home treatment with recombinant activated factor VII: results from one centre Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 9(Suppl 1): S107-S110
Tendera, M.; Campbell, W.B.; Tennant, S. 1986: Arrhythmia occurring during intracoronary thrombolytic treatment of patients with myocardial infarction Kardiologia Polska 29(10): 673-680
Radeschi, G.; Boris, E.F.; Sega, P.; Odetto, L.; Venturino, S. 2007: Utilization of recombinant activated factor VIi in a case of spontaneous massive haemothorax in a patient with Von Recklinghausen's disease Minerva Anestesiologica 73(4): 241-244
Galstian, G.M.; Kolosova, I.V. 2014: Using recombinant activated blood coagulation factor VIi for treatment of hemorrhagic syndrome in patients with thrombocytopenia Anesteziologiia i Reanimatologiia 59(6): 60-66
Smaradottir, A.; Bona, R. 2004: A case of acquired von Willebrand syndrome successfully treated with recombinant Factor VIIa during thyroidectomy Thrombosis and Haemostasis 92(3): 666-667
Vyhovs'ka, I.I.; Karol', I.S.; Fedak, L.M.; Tsytsyk, O.I. 2004: Use of recombinant activated factor VIi (NovoSeven) in the treatment of a patient with idiopathic thrombocytopenic purpura complicated with subarachnoid and parenchimatous hemorrhage Likars'ka Sprava 7: 77-81
Seidlová, D.; Blatný, J.; Penka, M.; Ovesná, P.; Brabec, P.; Sevcík, P.; Ventruba, P.; Cerný, V. 2010: Recombinant activated factor VIi in the treatment of life threatening post-partum haemorrhage; registry UniSeven in the Czech Republic Ceska Gynekologie 75(4): 297-305
Kącka, K.; Kącki, W.; Merak, J.; Błęka, A. 2010: Use of recombinant activated factor VII for reduction of perioperative blood loss during elective surgical correction of spine deformity in a Jehovah's Witness. Case report Ortopedia, Traumatologia, Rehabilitacja 12(5): 448-458
Devecioğlu, O.; Unüvar, A.şe.ül.; Anak, S.; Bilge, I.; Ander, H.; Ziylan, O. 2003: Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VIi and platelet transfusions Turkish Journal of Pediatrics 45(1): 64-66
Espevik, T.; Figari, I.S.; Ranges, G.E.; Palladino, M.A. 1988: Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1 Journal of Immunology 140(7): 2312-2316
Zhou, Q.; Li, J.; Luo, X.-P.; Shi, H.-M.; Chen, H.; Zhao, B.-L.; Zhu, J.; Ni, H.-C.; Shen, W.; Wang, C.-P. 2011: Relationship between post-stenting coronary thrombolysis in myocardial infarction flow and plasma von Willebrand factor and ADAMTS-13 levels in patients with ST segment elevation myocardial infarction Zhonghua Xin Xue Guan Bing Za Zhi 39(3): 212-216
Singleton, E.; Smith, J.; Kavanagh, M.; Nolan, B.; White, B. 2007: Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIIi Thrombosis and Haemostasis 98(6): 1188-1192
Grochova, M.; Kalnasova, B.; Firment, J.; Olejarova, I.; Roland, R.; Lazurova, I. 2011: Pulmonary administration of activated recombinant factor VIi Bratislavske Lekarske Listy 112(1): 29-33
Doix, S.; Mahrousseh, M.; Jolak, M.; Laurent, Y.; Lorenzini, J.L.; Binquet, C.; Zeller, M.; Cottin, Y.; Wolf, J.E. 2003: Factor V Leiden and myocardial infarction: a case, review of the literature with a meta-analysis Annales de Cardiologie et d'Angeiologie 52(3): 143-149
Pajares, A.; Larrea, L. 2006: Activated recombinant factor VII for bleeding after a kidney transplant: reflections Revista Espanola de Anestesiologia y Reanimacion 53(4): 266-7; author reply 268
Soots, G.; Lerche, E.; Nathaniels, E.K. 1970: 2 cases of successfully operated septal perforation occurring after myocardial infarction Chirurgie; Memoires de l'Academie de Chirurgie 96(4): 301-308
Aleksandrow, W.; Borkowski, P.; Iwanowski, L.; Kwiatkowski, W.; Roszczyk, R.; Ostrowska, B. 1989: Intravenous streptokinase treatment of acute myocardial infarction. I. Effect of the treatment on the course of infarction and the patency of the artery supplying the infarction area Kardiologia Polska 32(4): 194-201
Grinţescu, I.; Tulbure, D.; Mirea, L. 2006: Activated recombinant factor VIi (Novoseven) in multiple trauma patients: an outcome analysis Chirurgia 101(6): 615-624